CClinicalTrials.gg
CompletedNCT04995055Updated Jun 6, 2023Results posted

Evaluation of Multifocal Contact Lens Designs With and Without an HEV Blocker on Visual Function

An interventional study of JJVC Investigational Multifocal Contact Lens TEST Lens and ACUVUE® OASYS Multifocal in Visual Acuity, sponsored by Johnson & Johnson Vision Care, Inc.. Completed at 1 site in United States. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by Johnson & Johnson Vision Care, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

This is a single-masked, bilateral, controlled, randomized, 2x2 crossover, non-dispensing clinical trial to characterize the effects of an HEV-Blocker on several measures of visual function in a presbyopic population.

02

Conditions studied

  • Visual Acuity
03

In context

Lead sponsor

Johnson & Johnson Vision Care, Inc. is the lead sponsor of 220 studies on the registry; 2 are open to participants now.

Of its 110 completed or terminated interventional studies of FDA-regulated products, 101 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Potential subjects must satisfy all of the following criteria to be enrolled in the study:

    1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form
    2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
    3. Be between at least 40 and not more than 70 years of age at the time of screening.
    4. Possess a wearable pair of spectacles that provide correction for distance vision.
    5. Be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration).
    6. Be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".
    7. The subject must have normal color perception as evidenced by reading 17 out of the first 21 Ishihara plates correctly.
    8. The subject's distance spherical equivalent of their refraction must be in the range of -1.00 D to -4.00 D.
    9. The subject's refractive cylinder must be ≤0.75 D in each eye.
    10. The subject's ADD power must be in the range of +0.75 D to +2.50 D in each eye.
    11. The subject must have best corrected distance visual acuity of 20/20-3 or better in each eye.

Exclusion criteria

Exclusion Criteria:

  • Potential subjects who meet any of the following criteria will be excluded from participating in the study:

    1. Be currently pregnant or lactating.
    2. Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study.
    3. Use of any of the following oral medications within 1 week prior to enrollment: oral retinoids, oral tetracyclines, oral phenothiazines, anticholinergics, oral/inhaled steroids, oral phosphodiesterase type 5 inhibitors, interferon alfa, antimycobacterial antibiotics, and nitroimidazole antibiotics. See Section 9.1 for additional details regarding excluded systemic medications.
    4. Any current use of ocular medication with the exception of rewetting drops.
    5. Any known hypersensitivity or allergic reaction to single use preservative free rewetting drops or sodium fluorescein.
    6. Any previous or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK dacryocystorhinostomy, cataract surgery, retinal surgery, peripheral iridotomy/iridectomy, etc.).
    7. Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.
    8. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
    9. Any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
    10. A history of amblyopia, strabismus or binocular vision abnormality.
    11. History of optic nerve or retinal disease or trauma
    12. Abnormal color vison.
    13. Any other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, or corneal distortion
    14. Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA scale.
    15. Any current ocular infection or inflammation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Period 1

    Eligible subjects will be randomly assigned to contact lens wear sequence TEST/CONTROL in a bilateral fashion.

    Device: JJVC Investigational Multifocal Contact Lens TEST Lens · Device: ACUVUE® OASYS Multifocal

  • Experimental
    Period 2

    Eligible subjects will be randomly assigned to contact lens wear sequence CONTROL/ TEST in a bilateral fashion.

    Device: JJVC Investigational Multifocal Contact Lens TEST Lens · Device: ACUVUE® OASYS Multifocal

Interventions

  • DeviceJJVC Investigational Multifocal Contact Lens TEST Lens

    TEST Lens

  • DeviceACUVUE® OASYS Multifocal

    CONTROL Lens

06

What researchers measure

Primary outcomes

  1. Starburst Diameter (mm)

    The starburst diameter (mm) was measured each subject binocularly. Starburst diameter was quantified by the horizontal spread of the spokes emerging from the center of a small, point-like stimulus. A calibrated custom-made micrometer (two sides with reverse threading) was used to spread two posts out from a central mid-point. The posts attach to a custom-designed ruler that indicates the lateral spread of the starburst. Measurements for this metric are positive. Smaller diameter indicates better lens performance. The average diameter (mm) for each lens type was reported by period.

    Time frame: 30-minutes post lens insertion

  2. Halos Diameter (mm)

    Halo diameter (mm) was quantified and measured using the same micrometer as for starbursts diameter (mm). The Halo diameter (mm) was measured each subject binocularly. Measurements for halo diameter are positive, where smaller values indicate better performance. The average diameter (mm) for each lens type.

    Time frame: 30-minutes post lens insertion

  3. Glare Disability Threshold

    Glare disability threshold was collected binocularly for each subject. Subjects were exposed to a target stimulus for 2 seconds; before the measurement was taken the annulus was set to a level below that which would cause the target stimulus to be veiled. The experimenter would then adjust the intensity of the annulus until subjects could no longer see the target stimulus. Subjects would indicate this by pressing a buzzer. Glare disability thresholds take on positive values, where higher values indicate better lens performance. The average glare disability level (change in log relative energy) for each lens type was reported.

    Time frame: 30-minutes post lens insertion

Secondary outcomes

  1. Glare Discomfort (mm)

    The Glare discomfort was evaluated by calculating the change in height of the palpebral fissure measured while the participant views the mid-wave central grating target, compared to the maximal squint during a 5-second Photostress exposure induced by a solid, 10-degree broadband field, which completely obscures the target (\~10-deg diameter). Both eyes were recorded and averaged, to produce an average palpebral fissure height before and during the Photostress exposure. Glare discomfort can take on negative and positive values, where smaller values indicate better lens performance. The average glare discomfort (change in palpebral fissure height) for each lens type was reported.

    Time frame: 30-minutes post lens insertion

  2. Heterochromatic Contrast Threshold (HCT)

    Using the same optical bench set-up described Glare Disability Threshold, to measure HCT, participants viewed the mid-wave (580 nm) grating target presented on presented on a short wave (460 nm) "sky-light background." The intensity of the background was adjusted, until the participant was no longer able to resolve the grating target. The log relative energy of the background needed to obscure the central target was recorded as HCT. Heterochromatic contrast thresholds are positive values, where higher values indicate better lens performance. The average threshold each lens type was reported.

    Time frame: 30-minutes post lens insertion

  3. Two-Point Threshold (mm) With 403nm Filter

    To create the two-point threshold stimulus, a single point- source like stimulus was spread into two distinct points of light, using a custom-built, collapsible light baffle. The two-point threshold was quantified as the minimum distance (mm) at which a participant could detect two distinct points of light, separated by a small black space. Measurements for this metric are positive. Smaller distances indicate better lens performance. The average distance for each lens type and period.

    Time frame: 30-minutes post lens insertion

  4. Two-Point Threshold (mm) Without 403nm Filter

    To create the two-point threshold stimulus, a single point- source like stimulus was spread into two distinct points of light, using a custom-built, collapsible light baffle. The two-point threshold was quantified as the minimum distance (mm) at which a participant could detect two distinct points of light, separated by a small black space. Measurements for this metric are positive. Smaller distances indicate better lens performance. The average distance for each lens type.

    Time frame: 30-minutes post lens insertion

07

Results

Posted Jun 6, 2023

Participant flow

A total of 37 subjects were enrolled into this study. Of those enrolled, 35 were fit into at least 1 study lens, while 2 subjects failed to meet all eligibility criteria. Of those dispensed, 25 subjects completed the study, while 10 subjects were discontinued.

Period 1
Participant flow — Period 1
MilestoneSenofilcon A\Senofilcon A (C3)Senofilcon A (C3)\ Senofilcon A
Started1718
Completed1213
Not completed55
Withdrew: Covid-19 related10
Withdrew: Withdrawal by subject01
Withdrew: Subject discontinued due to timing44
Period 2
Participant flow — Period 2
MilestoneSenofilcon A\Senofilcon A (C3)Senofilcon A (C3)\ Senofilcon A
Started1213
Completed1213
Not completed00

Outcome measures

PrimaryStarburst Diameter (mm)

The starburst diameter (mm) was measured each subject binocularly. Starburst diameter was quantified by the horizontal spread of the spokes emerging from the center of a small, point-like stimulus. A calibrated custom-made micrometer (two sides with reverse threading) was used to spread two posts out from a central mid-point. The posts attach to a custom-designed ruler that indicates the lateral spread of the starburst. Measurements for this metric are positive. Smaller diameter indicates better lens performance. The average diameter (mm) for each lens type was reported by period.

Time frame:
30-minutes post lens insertion
Reported as:
Mean · mm
Starburst Diameter (mm)
mmSenofilcon ASenofilcon A (C3)
Period 177.06 ± 25.90064.13 ± 27.703
Period 267.26 ± 30.99154.24 ± 22.706
PrimaryHalos Diameter (mm)

Halo diameter (mm) was quantified and measured using the same micrometer as for starbursts diameter (mm). The Halo diameter (mm) was measured each subject binocularly. Measurements for halo diameter are positive, where smaller values indicate better performance. The average diameter (mm) for each lens type.

Time frame:
30-minutes post lens insertion
Reported as:
Mean · mm
Halos Diameter (mm)
mmSenofilcon ASenofilcon A (C3)
Halos Diameter (mm)69.24 ± 19.03352.93 ± 17.725
Statistical analysis
  • Senofilcon A vs Senofilcon A (C3) · Linear Mixed Model · Least-square mean difference: -15.4 · 95% CI -21.2 to -9.5Least-square Mean difference was calculated as senofilcon A (C3)- senofilcon A
PrimaryGlare Disability Threshold

Glare disability threshold was collected binocularly for each subject. Subjects were exposed to a target stimulus for 2 seconds; before the measurement was taken the annulus was set to a level below that which would cause the target stimulus to be veiled. The experimenter would then adjust the intensity of the annulus until subjects could no longer see the target stimulus. Subjects would indicate this by pressing a buzzer. Glare disability thresholds take on positive values, where higher values indicate better lens performance. The average glare disability level (change in log relative energy) for each lens type was reported.

Time frame:
30-minutes post lens insertion
Reported as:
Mean · log (change in log relative energy)
Glare Disability Threshold
log (change in log relative energy)Senofilcon ASenofilcon A (C3)
Glare Disability Threshold2.62 ± 0.2352.86 ± 0.179
Statistical analysis
  • Senofilcon A vs Senofilcon A (C3) · Linear Mixed Model · Least-square mean difference: 0.3 · 95% CI 0.2 to 0.4Least-square Mean difference was calculated as senofilcon A (C3)- senofilcon A
SecondaryGlare Discomfort (mm)

The Glare discomfort was evaluated by calculating the change in height of the palpebral fissure measured while the participant views the mid-wave central grating target, compared to the maximal squint during a 5-second Photostress exposure induced by a solid, 10-degree broadband field, which completely obscures the target (\~10-deg diameter). Both eyes were recorded and averaged, to produce an average palpebral fissure height before and during the Photostress exposure. Glare discomfort can take on negative and positive values, where smaller values indicate better lens performance. The average glare discomfort (change in palpebral fissure height) for each lens type was reported.

Time frame:
30-minutes post lens insertion
Reported as:
Mean · mm
Glare Discomfort (mm)
mmSenofilcon ASenofilcon A (C3)
Glare Discomfort (mm)9.88 ± 4.1646.61 ± 3.151
Statistical analysis
  • Senofilcon A vs Senofilcon A (C3) · Linear Mixed Model · Least-square mean difference: -3.5 · 95% CI -4.9 to -2.1Least-square Mean difference was calculated as senofilcon A (C3)- senofilcon A
SecondaryHeterochromatic Contrast Threshold (HCT)

Using the same optical bench set-up described Glare Disability Threshold, to measure HCT, participants viewed the mid-wave (580 nm) grating target presented on presented on a short wave (460 nm) "sky-light background." The intensity of the background was adjusted, until the participant was no longer able to resolve the grating target. The log relative energy of the background needed to obscure the central target was recorded as HCT. Heterochromatic contrast thresholds are positive values, where higher values indicate better lens performance. The average threshold each lens type was reported.

Time frame:
30-minutes post lens insertion
Reported as:
Mean · log (change in log relative energy)
Heterochromatic Contrast Threshold (HCT)
log (change in log relative energy)Senofilcon ASenofilcon A (C3)
Heterochromatic Contrast Threshold (HCT)1.85 ± 0.2212.14 ± 0.295
Statistical analysis
  • Senofilcon A vs Senofilcon A (C3) · Linear Mixed Model · Least-square mean difference: 0.3 · 95% CI 0.2 to 0.4Least-square Mean difference was calculated as senofilcon A (C3)- senofilcon A
SecondaryTwo-Point Threshold (mm) With 403nm Filter

To create the two-point threshold stimulus, a single point- source like stimulus was spread into two distinct points of light, using a custom-built, collapsible light baffle. The two-point threshold was quantified as the minimum distance (mm) at which a participant could detect two distinct points of light, separated by a small black space. Measurements for this metric are positive. Smaller distances indicate better lens performance. The average distance for each lens type and period.

Time frame:
30-minutes post lens insertion
Reported as:
Mean · mm
Two-Point Threshold (mm) With 403nm Filter
mmSenofilcon ASenofilcon A (C3)
Period 116.49 ± 5.6007.51 ± 2.889
Period 213.21 ± 5.0219.50 ± 6.321
SecondaryTwo-Point Threshold (mm) Without 403nm Filter

To create the two-point threshold stimulus, a single point- source like stimulus was spread into two distinct points of light, using a custom-built, collapsible light baffle. The two-point threshold was quantified as the minimum distance (mm) at which a participant could detect two distinct points of light, separated by a small black space. Measurements for this metric are positive. Smaller distances indicate better lens performance. The average distance for each lens type.

Time frame:
30-minutes post lens insertion
Reported as:
Mean · mm
Two-Point Threshold (mm) Without 403nm Filter
mmSenofilcon ASenofilcon A (C3)
Two-Point Threshold (mm) Without 403nm Filter8.63 ± 3.3915.47 ± 1.953
Statistical analysis
  • Senofilcon A vs Senofilcon A (C3) · Linear Mixed Model · Least-square mean difference: -3.1 · 95% CI -4.4 to -1.9Least-square Mean difference was calculated as senofilcon A (C3)- senofilcon A

Adverse events

Collected over Throughout the duration of the study; approximately 5- 10 days per subject.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Senofilcon A (C3)0/30 (0%)0/30 (0%)0/30 (0%)
Senofilcon A0/30 (0%)0/30 (0%)0/30 (0%)

Baseline characteristics

All subjects fitted at least one study lens.

Age, Continuous
Age, Continuous(Years)Fitted Subjects
Mean51.8 ± 7.95
Sex: Female, Male
Sex: Female, Male(Participants)Fitted Subjects
Female30
Male5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fitted Subjects
Black or African American6
White29
Region of Enrollment
Region of Enrollment(Participants)Fitted Subjects
United States35
08

Study locations

1 site
  • University of Georgia
    Athens, Georgia 30602, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 12, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04995055
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Responsible party
Sponsor
First posted
Aug 6, 2021
Start date
Oct 25, 2021
Primary completion
Apr 14, 2022
Completion
Apr 14, 2022
Results posted
Jun 6, 2023
Last update
Jun 6, 2023

Study contacts

Johnson & Johnson Vision Care, Inc. Clinical Trial
study director · Johnson & Johnson Vision Care, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion